en News - BIOINFORMATICS BARCELONA News Thu, 08 Feb 2018 11:01:24 +0000 Thu, 08 Feb 2018 11:01:24 +0000 Houdini 2 (http://houdini.antaviana.cat/) http://www.bioinformaticsbarcelona.eu/news New portal allows users to navigate thousands of data on human genetic diversity

The international project 1000 genomes provides information on 2504 complete genomic sequences from 26 populations around the world. It is the most extensive global human genetic variation data set to date, with more than 84 million genetic differences catalogued. In order to make this information available and help with navigating through such a large amount of data, researchers from the Bioinformatics of Genomic Diversity group at the Universitat Autònoma de Barcelona (UAB), in collaboration with scientists from the Institute of Evolutionary Biology (IBE), a centre belonging to the CSIC and the Pompeu Fabra University (UPF), created the PopHuman browser, the largest available inventory of measures of genetic diversity along the human genome. This resource allows the exhaustive search of episodes of natural selection which have taken place in the human lineage and have left their print on the genome.

Human genetic variation is the set of genetic differences which distinguish our genomes, either among individuals within a population or between populations. There are no two genetically identical humans. On average, each of us is more than 99% genetically identical to any other person, while the less than 1% of genetic variants distinguishing our genomes are present in different frequencies in different human populations. The geographically and ancestrally more distant populations tend to differ more, although it is the differences between individuals within populations, especially in the African ones, the most important quantitatively in the set of the human genetic variation.

The study of the human genetic variation has significant evolutionary and medical applications. It has allowed to determine the origin of humanity in sub-Saharan Africa hundreds of thousands of years ago and subsequent human migrations, and it also helps in understanding how certain genetic variants have contributed to the adaptation of human populations to their environment in the whole planet. The description and explanation of the evolutionary forces controlling human genetic variation within and between populations is thus a fundamental goal of population genetics.

In an article published recently in the prestigious journal Nucleic Acids Research, the UAB and IBE researchers presented an exhaustive inventory of genetic diversity measures along the human genome from the data of the project 1000 genomes. This inventory captures the evolutionary properties of the sequences, and it is available to researchers through the PopHuman genome browser, an online portal allowing users to navigate the results through a graphical interface. PopHuman offers the most complete catalogue of estimates of human genetic variation so far in terms of number of genomes and populations analysed, and incorporates the genetic changes between the human and the chimpanzee genomes. 

In this way, PopHuman allows to detect from relatively recent selective episodes, such as those related to the establishment of agriculture in European and Asian populations some 10,000 years ago, to older episodes which have recurrently occurred throughout the past million years, such as the one observed in the region of the PRM1 gene, involved in the compaction of sperm DNA. Researchers are convinced that PopHuman will become the starting point for any exhaustive analysis of the different selective episodes which have taken place in the human lineage and have left their mark on the genome.


Contact researchers:

Sònia Casillas and Antonio Barbadilla
Institute of Biotechnology and Biomedicine (IBB)
Department of Genetics and Microbiology
Universitat Autònoma de Barcelona (UAB)
Tel: +34 93 586 8958

Original article:

Sònia Casillas, Roger Mulet, Pablo Villegas-Mirón, Sergi Hervas, Esteve Sanz, Daniel Velasco, Jaume Bertranpetit, Hafid Laayouni, Antonio Barbadilla. "PopHuman: the human population genomics browser." 2018. Nucleic Acids Research, 46(D1):D1003-D1010. https://doi.org/10.1093/nar/gkx943. Impact Factor: 10.162.

Thu, 08 Feb 2018 11:01:24 +0000 http://www.bioinformaticsbarcelona.eu/news//news/97/new-portal-allows-users-to-navigate-thousands-of-data-on-human-genetic-diversity http://www.bioinformaticsbarcelona.eu/news/97 0
Bioinformatics firm Mind the Byte acquires Intelligent Pharma

Bioinformatics firm Mind the Byte, a pioneer in the development of technologies based on artificial intelligence, cloud and big data for computational drug design, has acquired 100% of Intelligent Pharma, one of the leaders in Spain in chemoinformatics services for the pharmaceutical and biotechnology industry.

Since they were established in 2011 and 2007 respectively, both firms which are based in the Barcelona Science Park have managed to raise €5.8 million in public and private capital and position themselves at the forefront of the sector.

This deal is the largest corporate operation to date in the emerging Spanish bioinformatics market and makes Mind the Byte the leading company in Spain and one of the largest companies in Europe in artificial intelligence applied to medicine discovery and development.

The terms of the agreement have not yet been made public but they include one part in cash and the other as a share swap. Mind the Byte is to finance the integration and growth of both firms with a capital increase, the third in its history, coming to €3 million.

"This transaction is part of Mind the Byte's business plan for the company's growth and internationalisation through strategic acquisitions," said Alfons Nonell-Canals, founder and CEO of the company. "The integration of Intelligent Pharma will mean we can benefit from its valuable network of contacts, equipment, technology and offices while also increasing our market share straight away. Our forecast for 2019 is to reach €2 million in turnover."

Mind the Byte, an Amazon Web Services technology partner since 2013, delivers its technology through a SaaS (Software as a Service) platform and high added value scientific services. In 2015 it opened its first European subsidiary in the Copenhagen Bio Science Park (Denmark) while in 2016 it moved into the Japanese market with local firm Filgen where it expects to achieve €1.2 million in turnover by 2020.

The acquisition of Intelligent Pharma, which has offices in Munich and Heidelberg (Germany), London (United Kingdom) and Alberta (Canada) and clients in over 20 countries worldwide, will enable the Catalan bioinformatics firm to expand its local and global footprint while also extending its range of services and speeding up its product innovation in the geographical areas where it has a presence.

"The integration will allow us to round off our portfolio of tools for designing drugs with the knowhow built up by Intelligent Pharma over more than 10 years in the market and technologies which add to those of Mind the Byte, something that will be very handy when it comes to enhancing our line of business," affirmed Nonell-Canals.

An emerging market with great potential

Bioinformatics is an emerging science in which computer science and information technology are applied to processing biological data. Chemoinformatics used for drug discovery is a key technology in this strategic area and one of the essential tools for R&D in the pharmaceutical industry since it enables reducing the time and cost of drug discovery and shortening the time to market for new medicines.

 "It can take 10 or 15 years and extremely long-term investment coming to hundreds of millions of euro to develop a drug," pointed out Nonell-Canals.  "With the help of bioinformatics, we can help cut that time, and the cost and risk of investment by streamlining the molecule discovery phase. Moreover, under our recent agreement with the Swedish firm Prosilico, we now also advise companies in the preclinical studies phase."

Data in the most recent report by international consultants Transparency Market Research (TMR) show that the world bioinformatics market is growing exponentially and the $2.3 billion valuation in 2012 is expected to reach $9.1 billion by the end of 2018.

Tue, 16 Jan 2018 12:23:49 +0000 http://www.bioinformaticsbarcelona.eu/news//news/95/bioinformatics-firm-mind-the-byte-acquires-intelligent-pharma http://www.bioinformaticsbarcelona.eu/news/95 0
Genes identified that distinguish mammals from other animals

What distinguishes Homo sapiens from other living beings? And the group of mammals? What makes them different? These are the questions that researchers from GRIB (IMIM-UPF) together with researchers of the Department of Experimental and Health Sciences from the UPF have been trying to answer. To do this, they analysed the already-sequenced genomes of 68 mammals and identified 6,000 families of genes that are only found in these animals. These are genes with no homologues outside mammals, in other words, they are not present in other hairless species. In humans, it is estimated that they represent 2.5% of the genes that code for proteins. The work was led by Dr. José Luis Villanueva-Cañas, a member of the Evolutionary Genomics group of GRIB and currently a researcher at the Evolutionary Biology Institute (UPF-CSIC), and Dr. Mar Albà, ICREA researcher and head of the Evolutionay Genomics group of GRIB. The study also involved Dr. David Andreu's group from the UPF. It has been published in the journal Genome Biology and Evolution.

Dr. Villanueva-Cañas explains that the aim of the work was to "understand which genes define mammals as a class, in other words, which genes are only found in this group". To do this, he designed a set of programs that made it possible to compare the genomes of 68 mammals. These included Homo sapiens, as well as other primates and representatives of the main orders of this class of animals, including the Iberian lynx. With this data he generated a catalogue of genes exclusive to the mammals, of around 6,000 families of genes. At the same time, he assigned them a possible age of origin according to the species in which they are present. He also tried to figure out what these genes do, using expression data (RNA sequencing) from different tissues, to see where and how they are expressed, and proteomic data to check if they are translated, in other words, produce proteins.

Some of these genes have a de novo origin, and do not come from the duplication of pre-existing genes. De novo genes are important for acquiring new functions during evolution, as was demonstrated by another study led by Dr. Albà (Origins of de novo genes in human and chimpanzee, published in Plos Genetics). The new study has managed to identify the functions of some of these genes, related to how the skin is structured and why it is different from that of, for example, reptiles, as well as other genes involved in the mammary glands characteristic of mammals. They have also identified antimicrobial peptides, which participate in the body's defence against pathogens.

The researchers also stress that the genes they have found are short and usually only expressed in one, or just a few tissues. Dr. Albà wants to highlight that "Studies like this help us understand how new genes form during evolution and whether they play an important role in the adaptation of organisms to their environment". For this reason, "cataloguing mammal genes is the first step in understanding their functions" and "brings us closer to defining a set of pieces that originated at the start of their evolution and which are common to all of them, or some of their subgroups". Dr. Villanueva-Cañas explains that "We still we do not know the function of an important part of our genes, so it is necessary to make an effort to characterise them." This is the case of one that was identified during the study (neuronatin), which plays a so-far-unknown role in brain development.

Reference article: Villanueva-Cañas JL, Ruiz-Orera J, Agea MI, Gallo M, Andreu D; Alba MM. New Genes and Functional Innovation in Mammals. Genome Biology and Evolution, 2017; 9, 1886-1900. DOI: 10.1093/gbe/evx136

Tue, 05 Dec 2017 11:04:24 +0000 http://www.bioinformaticsbarcelona.eu/news//news/93/genes-identified-that-distinguish-mammals-from-other-animals http://www.bioinformaticsbarcelona.eu/news/93 0
Mind the Byte and Prosilico sign a strategic partnership agreement
  • Together, the two companies will provide a broad portfolio of in silico models covering most aspects of virtual drug discovery and development.
  • Prosilico software will now be included in Mind the Byte's SaaS platform and both firms will promote each other's technologies.
  • This agreement fits with Mind the Byte's plans to expand internationally through strategic alliances and increase its range of services.

Mind the Byte, a bioinformatics company located at the Barcelona Science Park (PCB) and at Copenhagen BioScience Park (COBIS), announces that it has just signed an agreement to share technology with the Swedish-based company Prosilico. Within this partnership, Mind the Byte adds to its in silico drug discovery platform the capacity of doing some virtual predictions of human clinical ADME/PK and covers now a wider range of expertise and know-how.

The platform, which uses Cloud Computing, already allows studying the mechanism of action of drugs and conducting computational screenings for hit finding or drug repurposing. Now, it will be complemented with some Prosilico tools to predict relevant human in vivo ADME/PK properties in models independently validated by pharma companies.

The CEO of Mind the Byte Alfons Nonell-Canals says, "We have selected Prosilico as a partner because they have been able to utilize human clinical data to develop predictive models covering a wide range of ADME/PK applications and diminishing a lot of the otherwise common in vitro and in vivo experiments."

"Prosilico founding partners have documented their innovative work by a number of publications over the years and they bring a long big pharma experience from AstraZenca which makes Prosilico a very attractive partner for us," says Thomas Högberg, Chief Strategic Officer also from Mind the Byte.

On the other side, the CEO of Prosilico, Urban Fagerholm, concludes, "Mind the Byte is at the forefront of computational drug discovery providing a unique Software as a Service platform allowing also midsize pharma, biotechs and institutions an affordable and flexible access to High Performance Computing. We hope that being on this platform will advance the use of our human-based in silico ADME/PK tools and we look forward to the collaboration."

Thu, 30 Nov 2017 12:13:02 +0000 http://www.bioinformaticsbarcelona.eu/news//news/91/mind-the-byte-and-prosilico-sign-a-strategic-partnership-agreement http://www.bioinformaticsbarcelona.eu/news/91 0
Genomics prepares to jump to three dimensions

Genomics is one of the most rapidly evolving areas of biology. Over the last 15 years, the challenge of biologists has been to obtain the sequence of genes (one-dimensional information) in order to understand, for example, how changes in DNA fragments give rise to disease. "The great number of 1D genomics studies over the years has shown that the analysis of gene sequences, although providing important information, is not enough to understand the origin of complex diseases. Connections remain hidden and this is probably because they depend on a 3D signal that determines how genes are folded within the nucleus, and how and when they are made accessible to the cell," explains Modesto Orozco, a world expert in 3D genomics and head of the Bioinformatics and Molecular Modelling Lab at the Institute for Research in Biomedicine (IRB Barcelona).

Modesto Orozco, also Professor at the University of Barcelona, is co-organizing the Barcelona BioMed Conference: "Multidimensional Genomics: The 3D/4D organization of chromatin" together with Marc Martí-Renom from the CNAG/CRG in Barcelona and Giacomo Cavalli from the Institut de Génétique Humain/CNRS in France. The event, which begins today and runs until 15 November, will gather 20 world experts in 3D genomics from the US and Europe at the Institut d'Estudis Catalans in Barcelona. The initiative is organized by the Institute for Research in Biomedicine (IRB Barcelona) with the collaboration of the BBVA Foundation.

"Google Earth" applied to genomics

The invited speakers and 150 attendees share a common goal: to move from a one-dimensional vision of the genome to understand how chromatin, the DNA inside the cell's nucleus, is folded and how the structure of this folding can offer insight into how DNA works. "What we are shooting for is a sort of "Google Earth" applied to genomics," Orozco describes graphically. "A platform where we can see the two metres of the folded DNA molecule, and at the same time zoom in to atomic detail on a region that interests us in order to see the changes accumulated over time - 4D- due to external conditions, or to needs of the cells," he explains.

Is 3D/4D genomics a reality?

3D/4D genomics is a reality, although it is still at a very basic level of scientific research, far from clinical application, with several initiatives underway in the US and Europe. Within Europe, the three conference co-organizers are leading a Horizon 2020 project that aims to standardize the way in which 3D genomics projects are conducted, and how data are stored and exploited.

They aim to create a package of protocols, methodologies and processes that put order in a field that so far has none. "Techniques for 3D genomics are very new and there are gaps in how we process data, and this causes a sense of fragility, especially because results are difficult to reproduce," explains Orozco, coordinator of the European project.

During the conference, the developments made so far in the MuG (Multiscale Complex Genomics*) platform will be presented in a dedicated practical session with 70 participants. "The Barcelona BioMed Conference is a great opportunity to launch the platform internationally. It is based on a disruptive technology that allows scientists to connect to the platform from anywhere in the world and process their genomic data, switching very easily from one technique to another, with higher or lower resolution," describes Orozco.

For scientists, 3D genomic promises to afford a leap forward in personalized medicine and the treatment of diseases. "We are still far from using 3D genomics in applications for patients, but we will get there. Advances in this field will allow us to understand how the genome really works and how it is regulated, how we can impact this regulation, and the hidden reasons behind several diseases that today we simply can't understand," concludes the scientist.

"MuG has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 676556"

Fri, 17 Nov 2017 12:17:34 +0000 http://www.bioinformaticsbarcelona.eu/news//news/89/genomics-prepares-to-jump-to-three-dimensions http://www.bioinformaticsbarcelona.eu/news/89 0
The “DNA corrector” is more efficient in the most important regions of the genome

Error surveillance and repair mechanisms during DNA replication do not show the same competence in all regions of the human genome. Scientists headed by ICREA researcher Núria López-Bigas at the Institute for Research in Biomedicine (IRB Barcelona) reveal that the mechanism that repairs errors in DNA is more efficient in the regions of genes that hold information for the production of proteins.

The basic structure of genes is divided into exons and introns. The former hold the genetic sequences required to synthesise proteins, while most of the sequence of the latter hold less important information. Exons do not vary much between species, that is to say, they are similar between humans, mice and worms, for example. The accepted scientific explanation for this similarity is that exons are critical regions for the viability of an organism and therefore many mutations lead to lethal phenotypes and are therefore not observed.

"Negative selection is a key factor responsible for conserving exons between species, but we now know it is not the only factor. We demonstrate for the first time that exons hold fewer mutations than other regions because these regions are repaired more effectively" explains Núria López-Bigas, head of the Biomedical Genomics lab.

When DNA is copied, the molecule called polymerase-responsible for replication-places one nucleotide after the other in the sister sequence following the original sequence, but from time to time the wrong nucleotide is incorporated, thus causing an error. These errors can be corrected by the DNA mismatch repair machinery.

The researchers analysed colorectal tumours in which the polymerase carries a mutation, converting it to an error-prone polymerase. For this reason, these tumours contain a large number of mutations. By comparing the proportion of mutations in exons and introns, these scientists revealed that the former carry far fewer than what would be expected.

So they then went on to study the genomes of a type of paediatric brain cancer characterised not only by a mutated polymerase-like in the tumours previously examined-but also by an inactivated repair system. They observed that the number of mutations in the exons of these tumours was as high as that expected.

"The repair mechanism ensures that mutations do not accumulate in the genome, particularly in exons," explains Joan Frigola, PhD student and first author of the article together with postdoc Sabarinathan Radhakrishnan.

The scientists now have a clue as to the mechanism that makes the repair machinery in exons more efficient than in introns. This higher efficiency, they say, lies in exons having a very high content of a specific mark, H3K36me3, which allows greater recruitment of repair proteins to exons, thus making the repair process more efficient.

"Our repair machinery "knows" that it must focus on the most important regions of the genome. This point should be taken into consideration when studying DNA mutation and repair processes and in studies on evolution, whether in tumours or species," López-Bigas says.

The lab headed by López-Bigas began this research at the Pompeu Fabra University and completed it at IRB Barcelona. The study has been funded by the European Research Council (ERC), the UE's H2020 Programme, the Ministry of Economy and Competitiveness/European Regional Development Funds, and the Fundació La Marató de TV3.

Thu, 16 Nov 2017 14:14:15 +0000 http://www.bioinformaticsbarcelona.eu/news//news/87/the-dna-corrector-is-more-efficient-in-the-most-important-regions-of-the-genome http://www.bioinformaticsbarcelona.eu/news/87 0
How fast could dinosaurs move?

How fast could dinosaurs move? How can we know the size of sauropods with the measurements of their femur? What methods are there to calculate the weight of dinosaurs? These are some of the doubts that can be solved with an app for mobile devices designed by the lecturer Antonio Monleón-Getino, from the Department of Genetics, Microbiology and Statistics of the University of Barcelona, in collaboration with Biel Stela, member of the Research Programme on Biomedical Informatics (UPF-IMIM).

This app will be a new pedagogical and communicative tool to help the youngest audience to discover some of the hidden secrets of the fossilized skeleton of one of the most known dinosaurs which created great inspiration in the field of cinema and contributed to create its legend: the Tyrannosaurus rex. Discovered in Montana (United States) in September in 2013, this skeleton from 67 million years ago was rebuilt under the supervision of the palaeontologist Anne Schulp and the biologist Freek Vonk, and was moved to the Naturalis Biodiversity Center, the National Museum of Natural History of Leiden. It corresponds to one of the biggest predators that lived in the planet, with sharp teeth and a deathly bit, which was the terror of the animals in the Cretaceous. The fossilized skeleton presents the 80 % of volume of the original bone, which places this model in the first positions of the ranking of the most complete and well preserved skeletons of Tyrannosaurus rex worldwide. This good level of preservation results from the fact that, when it died, a thick layer of sand covered the skeleton.  

The collaboration with Antoni Monleón-Getino, member of the Research Group on Biostatistics and Bioinformatics (GRBIO) -integrated in the Bioinformatics Barcelona platform Association (BIB)- is part of the scientific advice promoted by the Institut Català de Paleontologia Miquel Crusafont for the exhibition "T. Rex. La Trix, el tiranosaure més ben conservat del món", in CosmoCaixa (Barcelona).  

Thu, 16 Nov 2017 11:19:12 +0000 http://www.bioinformaticsbarcelona.eu/news//news/85/how-fast-could-dinosaurs-move http://www.bioinformaticsbarcelona.eu/news/85 0
BIB, member of a European consortium to develop a Digital Skills on Computational Biology VOOC for Health Professionals

The European project "BioS - Digital skills on Computational Biology for Health Professionals" has been awarded with 1 million euro for the period 2018-2020 within the Erasmus+ Sector Skills Alliances in vocational education and training key action. BIB is part of a consortium lead by the Steinbeis-Hoschule Berlin (SHB) from Germany and formed by 13 European stakeholders, including SME and large enterprises, higher education and vocational training centres and associations from Germany, Spain, Greece, Belgium, Italy, Finland, Portugal and Cyprus.

The BioS project aims at advancing the skills of European medical doctors through the design, development and delivery of new modular vocational curricula on Digital Skills on Computational Biology, as well as transversal skills, straightforwardly responding to the skill gaps identified by existing research evidence.

The purpose is to provide medical doctors with knowledge, skills and competencies, which will allow them to tackle effectively concurrent challenges in EU healthcare systems, services, and policies, in benefit of the health of EU citizens.

The Erasmus+ Sector Skills Alliances aim at tackling skills gaps with regard to one or more occupational profiles in a specific sector. They do so by identifying existing or emerging sector-specific labour market needs (demand side), and by enhancing the responsiveness of initial and continuing vocational education and training (VET) systems, at all levels, to the labour market needs (supply side).

Fri, 03 Nov 2017 13:51:48 +0000 http://www.bioinformaticsbarcelona.eu/news//news/81/bib-member-of-a-european-consortium-to-develop-a-digital-skills-on-computational-biology-vooc-for-health-professionals http://www.bioinformaticsbarcelona.eu/news/81 0
Open innovation improving drug safety evaluation

The Hospital del Mar Medical Research Institute (IMIM) and the Pompeu Fabra University (UPF) have just published a comment in the prestigious journal Nature Reviews Drug Discovery where they explain the excellent results from eTOX, a project that has facilitated a new model for collaboration among pharmaceutical companies, as well as between these and academia, where data and knowledge are shared for the purposes of improving the toxicological evaluation of drugs.

Apart from the results obtained, which are extremely valuable, the project is a model of Open Innovation, where various public and private stakeholders join forces and actively collaborate. In addition, it has confirmed the enormous value of the data obtained in the regulatory studies conducted by the pharmaceutical industry, and has verified the fact that exploiting these requires a significant effort in terms of extraction, standardisation, and integration.

"The eTOX project has given us a glimpse into the potential of this data for constructing predictive models capable of foreseeing effects in vivo. However, it is necessary to incorporate toxicodynamic effects and analyse the extent to which the experimental data and predictions can be extrapolated to humans. To this end, we have just launched the new project eTRANSAFE", explains Ferran Sanz, the project coordinator and Director of the IMIM and UPF Biomedical Informatics programme (GRIB).

"One of the 'intangible' results of the project is the construction of a common language between partners with different professional profiles. Today, the computing experts know much more about toxicology than they did at the beginning of the project and we have a much deeper understanding of the problems and needs that exist in this area. The toxicologists have also learned a great deal and now have a better appreciation of the possibilities offered them by advanced computer and information technologies", adds Manuel Pastor, head of the FarmacoInformátics group at the GRIB.

An added value of the eTOX project is the development of technology that allows research results to be transferred to companies and sustainable results generated that can continue to be used beyond the end of the project.


Artícle of reference: "Legacy data sharing to improve drug safety assessment: the eTOX project" Ferran Sanz, François Pognan, Thomas Steger-Hartmann, Carlos Díaz and eTOX (including Manuel Pastor). Nature Reviews Drug Discovery, 2017.

Mon, 30 Oct 2017 15:35:36 +0000 http://www.bioinformaticsbarcelona.eu/news//news/79/open-innovation-improving-drug-safety-evaluation http://www.bioinformaticsbarcelona.eu/news/79 0
Interuniversity Doctorate Program in Bioinformatics: preregistration is open!

May we inform you that the interuniversity Doctorate Program in Bioinformatics is already running and that preregistration is open until November 15th. This is an official program jointly organized by the Universitat Atònoma de Barcelona (UAB), the Universitat Politècnica de Catalunya (UPC), the Universitat de Girona (UdG), the Universitat de Lleida (UdL), the Universitat Obert de Catalunya (UOC) and the Universitat de Vic - Universitat Central de Catalunya (UVic-UCC), with the participation of the Bioinformatics Barcelona Association (BIB). Preregistration can be formalized online through any of the participant universities.

You will find all the information in the corresponding web pages: UABUPCUdGUdLUOCUVic-UCC.

We also take the opportunity to inform you that the next preregistration period will be open from March 1st to May 15th, 2018, and that the admission notification will be due to June 1st, 2018.

You may contact Xavier Daura (xavier.daura@uab.cat) for any additional questions.

Fri, 02 Feb 2018 13:24:32 +0000 http://www.bioinformaticsbarcelona.eu/news//news/77/interuniversity-doctorate-program-in-bioinformatics-preregistration-is-open http://www.bioinformaticsbarcelona.eu/news/77 0